Saturday, October 3, 2026

EUR/JPY Bullish Momentum: 0.88% Up In The Last 5 Sessions

EUR/JPY Bullish Momentum: 0.88% Up In The Last 5 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 0.88% for the last 5 sessions. At 06:08 EST on Monday, 22 May, EUR/JPY (EURJPY) is $149.20.

EUR/JPY's yearly highs and lows, it's 11.831% up from its 52-week low and 1.576% down from its 52-week high.

Volatility

EUR/JPY's last week, last month's, and last quarter's current intraday variation average was 0.18%, 0.38%, and 0.57%, respectively.

EUR/JPY's highest amplitude of average volatility was 0.30% (last week), 0.65% (last month), and 0.57% (last quarter), respectively.

News about

  • Eur/usd price analysis: mildly bid above 1.0800 within bearish channel. According to FXStreet on Monday, 22 May, "It's worth noting that the RSI (14) line's rebound from nearly oversold conditions joins the EUR/USD pair's sustained break of the 100-DMA to keep Euro buyers hopeful.", "Even so, multiple hurdles around 1.0920 and 1.1000 may challenge the EUR/USD buyers before directing them to February's high of 1.1033. "
  • Eur/usd rebounds from 1.0800 as biden-mccarthy to discuss US debt-ceiling again on Monday. According to FXStreet on Sunday, 21 May, "The EUR/USD pair has shown a sharp recovery from near the round-level support of 1.0800 in the early Tokyo session. "
  • Eur/usd eases below 1.0850 as ECB hawks step back, fed bets increase amid cautious optimism. According to FXStreet on Monday, 22 May, "Moving on, Eurozone Consumer Confidence may direct intraday moves of the EUR/USD pair but major attention will be given to the first readings of the May month PMIs, as well as US debt ceiling talks for a clear guide."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com